within Pharmacolibrary.Drugs.ATC.J;

model J05AP56
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.25,
    adminDuration  = 600,
    adminMass      = 0.4,
    adminCount     = 1,
    Vd             = 0.045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>A fixed-dose combination of three direct-acting antivirals used for the treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir is an HCV NS5B polymerase inhibitor, velpatasvir is an NS5A inhibitor, and voxilaprevir is an NS3/4A protease inhibitor. This combination is approved for use in adults and certain pediatric populations and is marketed as Vosevi.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated based on individual PK data from the separate components in healthy adults after oral administration; no published population PK model was identified for the fixed-dose combination in the literature as of 2024-06.</p><h4>References</h4><ol><li>Julia Dietz, Velia Chiara Di Maio, Adolfo de Salazar, Dolores Merino, Johannes Vermehren, Stefania Paolucci, Andreas E Kremer, Magdalena Lara, Maria Rodriguez Pardo, Heinz Zoller, Elisabetta Degasperi, Kai-Henrik Peiffer, Laura Sighinolfi, Francisco Téllez, Christiana Graf, Valeria Ghisetti, Jonas Schreiber, Elisa Fernández-Fuertes, Lucio Boglione, Leopoldo Muñoz-Medina, Rudolf Stauber, William Gennari, Blanca Figueruela, Jesús Santos, Pietro Lampertico, Stefan Zeuzem, Francesca Ceccherini-Silberstein, Federico García, Christoph Sarrazin,Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.,Journal of hepatology,2021<a href='https://pubmed.ncbi.nlm.nih.gov/33220331/'>https://pubmed.ncbi.nlm.nih.gov/33220331/</a></li><li>B B Summers,Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.,Drugs of today (Barcelona, Spain : 1998),2018<a href='https://pubmed.ncbi.nlm.nih.gov/29869647/'>https://pubmed.ncbi.nlm.nih.gov/29869647/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AP56;
